Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          FDA Roundup: March 29, 2022Press Announcements FDA News Release
  FDA Roundup: March 29, 2022

  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  March 29, 2022
 

  
      
       

  Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

Today, the FDA authorized a manufacturing change for the Moderna COVID-19 Vaccine to include an additional presentation of the vaccine for booster vaccination doses only.  The new presentation is supplied in multiple dose vials with dark blue caps and labels with a purple border. The Moderna COVID-19 Vaccine is now authorized for individuals 18 years of age and older in two presentations: 1) multiple dose vials with red caps and labels with a light blue border, formulated to provide doses for primary vaccination (each 0.5 mL dose containing 100 microgram mRNA) or doses for booster vaccination (each 0.25 mL dose containing 50 microgram mRNA); and 2) multiple dose vials with dark blue caps and labels with a purple border, formulated to provide doses for booster vaccination only (each 0.5 mL dose containing 50 microgram mRNA).
	As part of the FDA’s effort to protect consumers, the agency issued warning letters jointly with the Federal Trade Commission to two companies for selling unapproved products with unproven COVID-19 claims. Consumers concerned about COVID-19 should consult with their health care provider. The companies that received warning letters are:
	Iodine Products Inc
		Applied Biological Laboratories Inc.
	Today, the FDA added information about leveraging validation data from a study on the adequacy of pediatric self-swabbing to collect a sample for COVID-19 diagnostic testing. The new information is found at COVID-19: Test Development and Review and includes: 
	The addition of the following question and answer:
		I want to offer my COVID-19 diagnostic test for pediatric self-swabbing. Is validation data available to leverage to support this indication?
		An update to the following question and answer:
		Can I leverage validation data that has already been reviewed by the FDA for another test?
	On March 28, a federal judge entered a consent decree of permanent injunction between the FDA and Bravo Packing, Inc., prohibiting the company from selling, manufacturing and distributing adulterated pet food until the firm takes specific corrective measures and demonstrates to the FDA that they will comply with the Federal Food, Drug and Cosmetic (FD&C) Act. Bravo Packing Inc., of Carneys Point, New Jersey, has had numerous health and safety violations and was issued a warning letter in 2020. This is the first consent decree of permanent injunction against an animal food manufacturer for violating public safety standards under Part 507 (Current Good Manufacturing Practice (CGMP) requirements) of the Food Safety Modernization Act (FSMA) Preventive Controls for Animal Food Regulation. Part 507 requires, among other things, that animal food facilities take adequate precautions to prevent animal food from becoming contaminated and that all animal food manufacturing, processing, packing, and holding is conducted under the conditions necessary to minimize the potential for the growth of undesirable microorganisms to protect against the contamination of animal food.
	As part of the FDA’s effort to protect consumers, the agency issued warning letters jointly with the Federal Trade Commission to seven companies for selling CBD products using research studies to claim or imply misleadingly that their CBD products will cure, mitigate, treat or prevent COVID-19. Consumers concerned about COVID-19 should consult with their health care provider. The companies that received warning letters are:
	Cureganics
		Heaven’s Organics LLC
		Functional Remedies, LLC D/B/A Synchronicity Hemp Oil
		Greenway Herbal Products LLC
		CBD Social
		UPSY LLC
		Nature’s Highway
	The FDA has not approved or authorized any drug containing CBD for the treatment or prevention of COVID-19. The agency is concerned these deceptive and misleading product claims could cause people to delay or stop appropriate medical treatment for COVID-19, leading to serious and life-threatening harm. Learn more about how to protect yourself from Fraudulent Coronavirus Tests, Vaccines and Treatments and report suspected health fraud.
	COVID-19 testing updates:
	As of today, 425 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 293 molecular tests and sample collection devices, 84 antibody and other immune response tests and 48 antigen tests. There are 74 molecular authorizations and 1 antibody authorization that can be used with home-collected samples. There is 1 EUA for a molecular prescription at-home test, 2 EUAs for antigen prescription at-home tests, 15 EUAs for antigen over-the-counter (OTC) at-home tests, and 3 for molecular OTC at-home tests.
		The FDA has authorized 28 antigen tests and 9 molecular tests for serial screening programs. The FDA has also authorized 906 revisions to EUA authorizations.Related Information
  
  Related Information
              FDA Newsroom

###
  Boilerplate
      The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Inquiries
  
    
        
         Media:
                 
      
                            FDA Office of Media Affairs
           
           
                      888-INFO-FDA
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      03/29/2022
               
               
Health Topic(s)
			  Infectious Disease
			    			       			    			       Coronavirus   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop